Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8458644 | Radiotherapy and Oncology | 2018 | 9 Pages |
Abstract
The planned dose escalation was not received by more than half-of-the patients. Robustness of the prostate target (CTV67.5) should therefore be better prioritized in these patients given the low toxicity profile. Estimates of delivered dose were less conservative for dose-accumulation due to interaction of random organ motion with the dose matrix.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Liv B. Hysing, Christian Ekanger, Ándras Zolnay, Svein Inge Helle, Mana Rasi, Ben J.M. Heijmen, Marcin Sikora, Matthias Söhn, Ludvig Paul Muren, Sara Thörnqvist,